Neurogene

Neurogene FCF/Debt

The Free Cash Flow to Debt Ratio of Neurogene (NGNE) as of Nov 20, 2026 is -792.19 %. In the previous year, Free Cash Flow to Debt Ratio was -574.60 % — a change of 37.87% (lower).

FCF/Debt

-792.19 %

YoY

37.87%

Last updated:

Free Cash Flow to Debt Ratio of Neurogene is 2025 -792.19 % . Free Cash Flow to Debt Ratio of Neurogene was 2024 -574.60 % . It decreases by 37.87% lower compared to the previous year.

The Neurogene FCF/Debt history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF/Debt
Date
FCF/Debt
Jan 1, 2018
-527,100.00 USD
Jan 1, 2019
-1,343.77 USD
Jan 1, 2020
-221.04 USD
Jan 1, 2021
-1,007.29 USD
Jan 1, 2022
-1,174.11 USD
Jan 1, 2023
-318.32 USD
Jan 1, 2024
-574.60 USD
Jan 1, 2025
-792.19 USD
The Neurogene FCF/Debt history
YEARFCF/DebtYoY
-792.19 %+37.87%
-574.60 %+80.51%
-318.32 %-72.89%
-1,174.11 %+16.56%
-1,007.29 %+355.71%
-221.04 %-83.55%
-1,343.77 %-99.75%
-527,100.00 %+284.72%
-137,010.21 %+108.13%
-65,827.66 %+324.90%
-15,492.37 %-37.46%
-24,770.82 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Neurogene Stock analysis

What does Neurogene do? Neurogene Inc develops genetic medicines for rare neurological diseases using its EXACT transgene regulation platform technology. The company focuses on creating treatments like NGN-401, an AAV9 gene therapy candidate for Rett syndrome, and NGN-101 for CLN5 Batten disease. These products target patients with devastating neurological conditions, aiming to overcome limitations of conventional gene therapy by delivering therapeutic levels while minimizing transgene toxicity. The firm advances multiple discovery-stage candidates through its proprietary technology. The company's revenue model relies on developing and advancing its product candidates through clinical stages, with NGN-401 and NGN-101 being the primary focus. Neurogene Inc. is a biotechnology firm that operates in the US, targeting patients affected by rare neurological diseases through its innovative gene therapy approaches. The company's products are designed to address unmet medical needs in central nervous system disorders, leveraging its EXACT platform to optimize therapeutic outcomes. Neurogene Inc. was formerly known as Neoleukin Therapeutics, Inc., and its business strategy centers on developing novel gene therapies for rare conditions. The company's EXACT technology enables precise transgene regulation, which is critical for treating neurological diseases where conventional gene therapy has shown limitations. By focusing on Rett syndrome and CLN5 Batten disease, Neurogene Inc. targets specific patient segments with high unmet medical needs, aiming to provide safer and more effective treatment options. Neurogene is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Neurogene stock

Free Cash Flow to Debt Ratio of Neurogene is -792.19 % in 2025.

Free Cash Flow to Debt Ratio of Neurogene changed from -574.60 % to -792.19 %, representing a 37.87% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Free Cash Flow to Debt Ratio Neurogene since 2006 – with annual values, charts, and detailed analysis.

FCF/Debt measures the percentage of total debt that could be repaid from free cash flow. It is a stricter measure than OCF/Debt as it accounts for capital expenditures.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Free Cash Flow to Debt Ratio's Neurogene with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Neurogene

All Key Metrics — Neurogene